Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise

Kyle LaHucik

Senior Reporter

An MPM Capital-backed biotech based on the discovery of a new immune checkpoint inhibitor has secured about $80 million in financing, with former executives from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Scoop: MPM backs a new check­point in­hibitor biotech in $80M raise

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?